Enfermedad de alzheimer. Situación actual y estrategias terapéuticas

Revista Cubana de Medicina

Volumn 38, Issue 2, 1999, Pages 134-142

  Llibre Rodríguez, Juan De J ^a   Guerra Hernández, Milagros A ^a  

^a HOSPITAL MILITAR CENTRAL DR CARLOS J FINLAY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 48849115322     PISSN: 00347523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cacabelos R. Enfermedad de Alzheimer. Epidemiología y etiopatología. FOMECD 1995;3(4):212-20.
2. Llibre Rodríguez J. Epidemiology of dementia and Alzheimer's diseases. Ann Psychiatr Basic Clin Neurosci 1997;7:2-7.
3. De Figuereido JM. Epidemiology of Alzheimer diseases. Research trends in the United States. Intern J Geriatr Psychiatr 1993;8:59-65.
4. Barry R. Alzheimer Disease. En: Comprehensive review of geriatric psychiatry. New York: J American Association for Geriatric Psychiatry, 1996:401-58.
5. th International Conference of Alzheimer's Disease International. Helsinki 1997.
6. León MJ de, George AE, Golomb J. Frequency of hippocampal formation atrophy in normal ageing Alzheimer's disease. Neurobiol Ageing 1997;18:1-11.
7. Iqbal K, Grundke I. Elevated levels of Tau and Ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease. Int Psycogeriatr 1997;9(1):289-96.
8. Kazze AM, Eski T, Laphan L, Gabriel K. Clinicopathologic correlates in Alzheimer's disease: assessment of clinical and pathological diagnostic criteria. Alzheimer Dis Asocc Disord 1993;7(3):1-3.
9. Rosemberg R. A casual role for amiloid in Alzheimer's disease: the end of the beginning. Neurology 1993;43:851-6.
10. Roses A, Saunders A. Apolipoprotein E genotyping as a diagnostic adjunct for Alzheimer's disease. Int Psychogeriatr 1997;9(1):277-88.
11. WWW. Science mag. Org. Science vol. 281 24 July 1998.
12. th International Conference of Alzheimer's Disease International. Helsinki. September 1997.
13. Mc Kahnn Y, Drackman D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Dept of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-47.
14. Cutler R. NIH Conference: Alzheimer's disease and Down syndrome: new insights. Ann Intern Med 1985;103:566-78.
15. Jané F. Tratamiento de la enfermedad de Alzheimer: situación actual y perspectivas. Rev Neurol (Barc) 1995;23(119):103-7.
16. th International Conference of Alzheimer's Disease International. Helsinki. 1997.
17. Rogers S, Friedhoff L, Donepezil Study Group. The efficacy and safety of donepezil inpatients with Alzheimer's disease: results of the US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996;29:312-21.
18. Kimura D. Estrogen replacement therapy may protect against intellectual decline in post menopausical women. Horm Behav 1995;29:312-21.
19. Tang M, Jacobs D, Stern Y, et al. Effects of destrogens during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
20. Amelsvdort T van, Murphy D. Oestrogens and Alzheimer's disease: the state of the art. Alzheimer's review. Magellan Med Commun 1997;7(2):152-5.
21. Cacabelos R, Caamaño J, Franco A, Fernández Novoa, Alvarez XA. Tratamiento farmacológico de la enfermedad de Alzheimer. JANO 1994;67(1105):25-54.
22. O'brier J, Barber B. Recent advances. IPA Bull 1997;14(2):16-9.
23. Shubert P, Ogata T, Rudolphi KA. Support of homeostatic glial cell signaling therapeutic approach by propentofiline. Ann New York Acad Sci 1997;826:337-46.
24. Alzheimer's disease. Am J Psychiatr 1997(suppl)154:5.